-5%
Mirtazapine is used for the treatment of major depressive disorder (MDD).
- The exact mechanism of Mirtazapine in treating depression is unknown.
- It enhances central noradrenergic and serotonergic activity by antagonizing central α2-adrenergic receptors.
- Acts as an antagonist of 5-HT2 and 5-HT3 receptors, increasing serotonin activity.
- Strong histamine (H1) antagonist, which contributes to its sedative effects.
- Moderate α1-adrenergic and muscarinic receptor antagonists lead to potential side effects like orthostatic hypotension.
Pharmacokinetics:
- Rapidly absorbed after oral administration, reaching peak plasma levels within 2 hours.
- Plasma protein binding: 85%.
- Half-life: 20-40 hours (26 hours in males, 37 hours in females), allowing for once-daily dosing.
- Metabolized primarily by demethylation and oxidation, followed by conjugation.
- Eliminated through urine and feces within four days.